Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose

ClinicalTrials.gov ID: NCT00150410

Public ClinicalTrials.gov record NCT00150410. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A One-Year, Open, Randomized, Parallel, Three-Arm Study Comparing Exubera® (Insulin Dry Powder Pulmonary Inhaler) vs. Avandia® (Rosiglitazone Maleate) as Add-On Therapy vs. Exubera® Substitution of Sulfonylurea in Patients With Type 2 Diabetes, Poorly Controlled on Combination Sulfonylurea and Metformin Treatment

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

* Whether a combination of three therapies - metformin and a sulfonylurea plus Exubera, an investigational drug, controls your diabetes at least as much as a triple combination therapy of metformin and a sulfonylurea plus Avandia, a Food and Drug Administration (FDA) approved drug. * Whether a combination of two therapies - metformin plus Exubera controls your diabetes at least as much as a as a triple combination therapy of metformin and a sulfonylurea plus Avandia.

Study identification

NCT ID
NCT00150410
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
626 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 2003 (Type not available)
Primary completion
Not listed
Completion
Jun 2007 (Actual)
Last update posted
Oct 31, 2008

2003 – 2007

United States locations

U.S. sites
88
U.S. states
37
U.S. cities
75
Facility City State ZIP Site status
Pfizer Investigational Site Mesa Arizona 85205 —
Pfizer Investigational Site Phoenix Arizona 85012 —
Pfizer Investigational Site Tucson Arizona 85715 —
Pfizer Investigational Site Searcy Arkansas 72143 —
Pfizer Investigational Site Alhambra California 91801 —
Pfizer Investigational Site Concord California 94520 —
Pfizer Investigational Site Huntington Beach California 92647 —
Pfizer Investigational Site Huntington Beach California 92648 —
Pfizer Investigational Site La Jolla California 92037 —
Pfizer Investigational Site Long Beach California 90805 —
Pfizer Investigational Site Long Beach California 90806 —
Pfizer Investigational Site Los Angeles California 90048 —
Pfizer Investigational Site Riverside California 92506 —
Pfizer Investigational Site Santa Barbara California 93105 —
Pfizer Investigational Site Tustin California 92780 —
Pfizer Investigational Site Westminster California 92683 —
Pfizer Investigational Site Denver Colorado 80209 —
Pfizer Investigational Site Wheat Ridge Colorado 80033 —
Pfizer Investigational Site Waterbury Connecticut 06708 —
Pfizer Investigational Site Washington D.C. District of Columbia 20010 —
Pfizer Investigational Site Washington D.C. District of Columbia 20307 —
Pfizer Investigational Site Hollywood Florida 33021 —
Pfizer Investigational Site West Palm Beach Florida 33401 —
Pfizer Investigational Site Winter Park Florida 32789 —
Pfizer Investigational Site Atlanta Georgia 30309 —
Pfizer Investigational Site Augusta Georgia 30909 —
Pfizer Investigational Site Savannah Georgia 31405 —
Pfizer Investigational Site Savannah Georgia 31419 —
Pfizer Investigational Site Honolulu Hawaii 96813 —
Pfizer Investigational Site ‘Ewa Beach Hawaii 96706 —
Pfizer Investigational Site Idaho Falls Idaho 83404-6370 —
Pfizer Investigational Site Idaho Falls Idaho 83404-7542 —
Pfizer Investigational Site Chicago Heights Illinois 60411 —
Pfizer Investigational Site Indianapolis Indiana 46202 —
Pfizer Investigational Site Des Moines Iowa 50314 —
Pfizer Investigational Site Wichita Kansas 67203 —
Pfizer Investigational Site Lexington Kentucky 40503 —
Pfizer Investigational Site Louisville Kentucky 40213 —
Pfizer Investigational Site Baton Rouge Louisiana 70808 —
Pfizer Investigational Site New Orleans Louisiana 70112 —
Pfizer Investigational Site Baltimore Maryland 21204 —
Pfizer Investigational Site Springfield Massachusetts 01103 —
Pfizer Investigational Site Springfield Massachusetts 01199 —
Pfizer Investigational Site Waltham Massachusetts 02453 —
Pfizer Investigational Site West Saint Paul Minnesota 55118 —
Pfizer Investigational Site North Kansas City Missouri 64116 —
Pfizer Investigational Site St Louis Missouri 63141 —
Pfizer Investigational Site Butte Montana 59701 —
Pfizer Investigational Site Lincoln Nebraska 68521 —
Pfizer Investigational Site New Brunswick New Jersey 08901 —
Pfizer Investigational Site New Brunswick New Jersey 08903 —
Pfizer Investigational Site Albuquerque New Mexico 87106 —
Pfizer Investigational Site Albany New York 12208 —
Pfizer Investigational Site Flushing New York 11365 —
Pfizer Investigational Site Mineola New York 11501 —
Pfizer Investigational Site New Hyde Park New York 11042 —
Pfizer Investigational Site Rochester New York 14642 —
Pfizer Investigational Site Raleigh North Carolina 27609 —
Pfizer Investigational Site Cincinnati Ohio 45229 —
Pfizer Investigational Site Cleveland Ohio 44195 —
Pfizer Investigational Site Lakewood Ohio 44107 —
Pfizer Investigational Site Oklahoma City Oklahoma 73104 —
Pfizer Investigational Site Portland Oregon 97210 —
Pfizer Investigational Site Pittsburgh Pennsylvania 15235 —
Pfizer Investigational Site Charleston South Carolina 29401-5799 —
Pfizer Investigational Site Charleston South Carolina 29425 —
Pfizer Investigational Site Duncan South Carolina 29334 —
Pfizer Investigational Site Spartanburg South Carolina 29303 —
Pfizer Investigational Site Spartanburg South Carolina 29307 —
Pfizer Investigational Site Sumter South Carolina 29150 —
Pfizer Investigational Site Kingsport Tennessee 37660 —
Pfizer Investigational Site Knoxville Tennessee 37909 —
Pfizer Investigational Site Memphis Tennessee 38119 —
Pfizer Investigational Site Nashville Tennessee 37232 —
Pfizer Investigational Site Corpus Christi Texas 78411 —
Pfizer Investigational Site Dallas Texas 75230 —
Pfizer Investigational Site Dallas Texas 75246 —
Pfizer Investigational Site El Paso Texas 79925 —
Pfizer Investigational Site El Paso Texas 79935 —
Pfizer Investigational Site San Antonio Texas 78229 —
Pfizer Investigational Site San Antonio Texas 78237 —
Pfizer Investigational Site Ogden Utah 84403 —
Pfizer Investigational Site Fredericksburg Virginia 22401 —
Pfizer Investigational Site Richmond Virginia 23221 —
Pfizer Investigational Site Richmond Virginia 23294 —
Pfizer Investigational Site Renton Washington 98055 —
Pfizer Investigational Site Tukwila Washington 98188 —
Pfizer Investigational Site Milwaukee Wisconsin 53209 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00150410, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 31, 2008 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00150410 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →